Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥3,400 JPY
Change Today +10.00 / 0.29%
Volume 57.9K
4547 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
As of 2:00 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

kissei pharmaceutical co ltd (4547) Snapshot

Open
¥3,390
Previous Close
¥3,390
Day High
¥3,410
Day Low
¥3,385
52 Week High
04/9/15 - ¥3,975
52 Week Low
05/26/14 - ¥2,223
Market Cap
184.7B
Average Volume 10 Days
100.1K
EPS TTM
¥140.87
Shares Outstanding
54.3M
EX-Date
09/28/15
P/E TM
24.1x
Dividend
¥44.00
Dividend Yield
1.24%
Current Stock Chart for KISSEI PHARMACEUTICAL CO LTD (4547)

Related News

No related news articles were found.

kissei pharmaceutical co ltd (4547) Related Businessweek News

No Related Businessweek News Found

kissei pharmaceutical co ltd (4547) Details

Kissei Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in Japan. Its product line includes Urief for the treatment of dysuria; Glufast and Glubes for type 2 diabetes; Salagen for patients with dry mouth; Epoetin Alfa BS injection to treat renal anemia; Bezatol for hyperlipidemia; Utemerin for the treatment of abortion and premature labor; Xanbon to treat acute cerebral thrombosis; Rizaben eye drops for allergic conjunctivitis; Rizaben to treat allergies, hypertrophic scars, etc.; and Domenan for the treatment of bronchial asthma. The company also provides nutritional foods comprising Yumegohan for patients with renal diseases; New Throking-i for seniors; and Cupagalorie energy supplement. Its product portfolio under development stage includes PA21, a Phase III clinical trial product for the treatment of hyperphosphatemia in hemodialysis patients; KPS-0373, which is in Phase III clinical trial for the treatment of spinocerebellar ataxia; KCT-0809 that is in Phase II clinical trial for dry eye; and KLH-2109, a Phase II clinical trial product for treating endometriosis/uterine fibroids. The company’s other products under development stage comprise KWA-0711, which is in Phase II clinical trial for the treatment of chronic constipation; KUX-1151, a Phase II clinical trial product for the treatment of gout and hyperuricemia; YS110, a Phase I/II clinical trial product to treat malignant mesothelioma; and KEA-0477, which is in Phase I clinical trial for overactive bladder. In addition, it provides information solution services, construction subcontracting services, and facilities and equipment management services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Matsumoto, Japan.

Founded in 1946

kissei pharmaceutical co ltd (4547) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kissei pharmaceutical co ltd (4547) Key Developments

Kissei Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Fiscal Year Ended March 2015; Provides Consolidated Earnings Guidance for the Full Year Ending March 2016

Kissei Pharmaceutical Co., Ltd. announced consolidated earnings results for the fiscal year ended March 2015. For the year, the company announced net sales of USD 584.3 million against USD 586.7 million a year ago. Operating income was USD 69.5 million against USD 102.5 million a year ago. Net income was USD 59.7 million against USD 75.8 million a year ago. The company provided consolidated earnings guidance for the full year ending March 2016. For the full year ending March 2016, the company expects to report net sales of USD 587.5 million, gross profit of USD 378.3 million, operating income of USD 72.5 million, and net income of USD 56.7 million.

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2015 results on May 12, 2015

Kissei Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 2014; Provides Earnings Guidance for the Full Year Ending March 2015

Kissei Pharmaceutical Co., Ltd. announced consolidated earnings results for the nine months ended December 2014. For the period, the company reported net sales of $436.3 million compared to $442.4 million a year ago. Operating income was $72.7 million compared to $96.7 million a year ago. Net income was $61.8 million compared to $72.3 million a year ago. For the full year ending March 2015, the company expects net sales of $569.7 million, operating income of $77.9 million, net income of $64.2 million and gross profit of $371.5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4547:JP ¥3,400.00 JPY +10.00

4547 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4547.
View Industry Companies
 

Industry Analysis

4547

Industry Average

Valuation 4547 Industry Range
Price/Earnings 23.6x
Price/Sales 2.3x
Price/Book 1.1x
Price/Cash Flow 25.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KISSEI PHARMACEUTICAL CO LTD, please visit www.kissei.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.